Review anchor
NACHT, LRR and PYD domains-containing protein 3
SINGLE PROTEIN · Mus musculus
As of 2026-09-13
Evidence Snapshot
NACHT, LRR and PYD domains-containing protein 3
CHEMBL3779755
SINGLE PROTEIN
Mus musculus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats NACHT, LRR and PYD domains-containing protein 3 as ChEMBL target CHEMBL3779755, mapped to UniProt Q8R4B8. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3779755
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q8R4B8
NACHT, LRR and PYD domains-containing protein 3
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why NACHT, LRR and PYD domains-containing protein 3 matters
NACHT, LRR and PYD domains-containing protein 3 is reviewed as NACHT, LRR and PYD domains-containing protein 3 (UniProt Q8R4B8); the current evidence base includes 5 approved drugs, 646 compounds, and 393 assays, with lead potency reaching pChEMBL 9.6.
Protein context
NACHT, LRR and PYD domains-containing protein 3
NACHT, LRR and PYD domains-containing protein 3 Sequence length is 1033 aa.
Review this target as NACHT, LRR and PYD domains-containing protein 3, mapped to UniProt Q8R4B8. Sequence length is 1033 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q8R4B8
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 5 approved drugs, 646 compounds, and 393 assays for this target. The dominant activity type is IC50. CHEMBL5184952 is the current potency anchor at pChEMBL 9.6.
Use CHEMBL5184952 as the tractability anchor when discussing potency (pChEMBL 9.6).
Activity source · ChEMBL 36 via Core Engine
5 approved
pChEMBL 9.6
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why NACHT, LRR and PYD domains-containing protein 3 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q8R4B8, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
646
Total Compounds
393
Total Assays
5
Approved Drugs
IC50: 528.0, KD: 2.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5184952
|
9.6 | IC50 | — |
|
|
No preferred name
CHEMBL3183703
|
9.4 | IC50 | — |
|
|
No preferred name
CHEMBL3989943
|
9.0 | IC50 | Clinical |
|
|
No preferred name
CHEMBL5421905
|
8.2 | IC50 | — |
|
|
No preferred name
CHEMBL4288808
|
8.1 | IC50 | — |
Source Header